Skip to main content

New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases

Objective

Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people. The current therapies, including antibodies, show three main drawbacks: efficacy, tolerability and convenience. NEW DEAL solution will offer radical therapeutic progress for all IBD patients, thanks to the improved efficacy and increased safety of the specific JAK3 inhibition, which has been proven in clinics to be a target of great interest, the better tolerability of siRNA in term of immunogenicity and the good convenience with oral administration. To achieve this challenge, we will address three objectives: i) Specifically inhibit JAK 3 in a highly selective and safer manner by the mean of siRNA carefully designed and validated, ii) Deliver the siRNA therapeutic locally to the inflamed gut, by combining innovative nanostructured lipid carriers enabling their transport across the mucus, the intestinal barrier and the plasma membrane of the target cells, with polymeric capsules for protecting siRNA nanotherapeutics during their transit along the GI tract, thus allowing an oral administration, and iii) Promote the clinical translation and the future industrial transfer of this new clinical product, by addressing manufacturing, safety and efficacy evaluation at the late preclinical stage, to generate a Regulatory Submission Package and a Clinical Development Plan. The NEW DEAL project brings together clinical experts on IBD, leading scientists in nanomedicine, RNAi biology and immunology, innovative SMEs with a strong background in nanosafety, design of capsules and regulatory issues and an established pharma company with historic expertise on gastroenterology medicinal products. If successful, NEW DEAL will open new avenues for siRNA-based therapy in IBD with oral administration.

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /medical and health sciences/medical biotechnology/nanomedicine
  • /medical and health sciences/basic medicine/immunology
  • /social sciences/social and economic geography/transport
  • /medical and health sciences/clinical medicine/gastroenterology
  • /medical and health sciences/clinical medicine/gastroenterology/inflammatory bowel disease

Call for proposal

H2020-NMBP-2016-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Address
Rue Leblanc 25
75015 Paris 15
France
Activity type
Research Organisations
EU contribution
€ 1 915 936,25

Participants (11)

EUROPEAN RESEARCH SERVICES GMBH
Germany
EU contribution
€ 233 337,50
Address
Roentgenstrasse 19
48149 Muenster
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany
EU contribution
€ 384 965
Address
Inhoffenstrasse 7
38124 Braunschweig
Activity type
Research Organisations
NANOIMMUNOTECH SL
Spain
EU contribution
€ 506 813,75
Address
Edificio Citexvi C Fonte Das Abelle Sn Campus Universitario De Vigo
36310 Vigo Pontevedra
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Spain
EU contribution
€ 774 723,75
Address
Calle Rossello 149 Puerta Bjs
08036 Barcelona
Activity type
Other
PRODIGEST
Belgium
EU contribution
€ 463 343,75
Address
Technologiepark 3
9052 Gent Zwijnaarde
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SEPS PHARMA
Belgium
EU contribution
€ 373 125
Address
Agoralaan Abis
3590 Diepenbeek
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SPARKS & CO

Participation ended

France
EU contribution
€ 43 886,94
Address
66 Avenue Des Champs Elysees Espace 41
75008 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 475 258,75
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
LABORATOIRES MAYOLY SPINDLER
France
EU contribution
€ 448 750
Address
6 Avenue De L'europe
78400 Chatou
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ALAN BOYD CONSULTANTS LIMITED
United Kingdom
EU contribution
€ 188 750
Address
Electra House, Crewe Business Park
CW1 6GL Crewe
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SCIENSEED SL
Spain
EU contribution
€ 190 288,06
Address
Calle Arte 3 5/A
28033 Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)